caa a22 4500 44531334X CHVBK 20180317142637.0 cr unu---uuuuu 170323e20110401xx s 000 0 eng 10.1007/s11095-010-0332-2 doi (NATIONALLICENCE)springer-10.1007/s11095-010-0332-2 Formation of Protein Nano-Matrix Particles with Controlled Surface Architecture for Respiratory Drug Delivery [Elektronische Daten] [Philip Kwok, Amolnat Tunsirikongkon, William Glover, Hak-Kim Chan] ABSTRACT: Purpose: To produce and examine the aerosol performance of protein nano-matrix particles with different surface roughness. Methods: Aqueous lysozyme solutions were poured into isopropanol during high-shear mixing to produce nanoparticles by precipitation. The size of the nanoparticles was varied by adjusting the precipitation conditions. The resultant suspensions were spray-dried to obtain micron-sized aggregates (nano-matrices). Smooth particles were made by spray-drying a lysozyme solution. The aggregate size distribution, surface roughness, and cohesion were evaluated. The aerosol performance was assessed by dispersing 10mg of powder from a Rotahaler® at 60L/min or an Aerolizer® at 100L/min into a Next Generation Impactor, followed by chemical assay (n = 3). Results: The median volume diameter and span of the nano-matrix particles were 1.0-1.2μm and 1.5-1.6, respectively, which were comparable to those of the smooth particles. Surface roughness increased with the size of the primary nanoparticles. The nano-matrix particles were significantly less cohesive than the smooth particles. The fine particle fraction increased linearly with increasing surface roughness and decreasing cohesion. Conclusions: Nano-matrix particles with controlled surface architecture were successfully produced by spray-drying nanosuspensions. Aerosol performance was enhanced with increasing surface roughness due to the reduction in cohesion forces. Springer Science+Business Media, LLC, 2010 aggregates nationallicence dispersion nationallicence lysozyme nationallicence nano-matrix nationallicence roughness nationallicence Kwok Philip Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Building A15, 2006, Camperdown, NSW, Australia aut Tunsirikongkon Amolnat Department of Pharmaceutics and Industrial Pharmacy Faculty of Pharmaceutical Sciences, Chulalongkorn University, Phyathai Road, Patumwan, 10330, Bangkok, Thailand aut Glover William GSK Consumer Health, 82 Hughes Avenue, 2115, Ermington, NSW, Australia aut Chan Hak-Kim Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Building A15, 2006, Camperdown, NSW, Australia aut Pharmaceutical Research Springer US; http://www.springer-ny.com 28/4(2011-04-01), 788-796 0724-8741 28:4<788 2011 28 11095 https://doi.org/10.1007/s11095-010-0332-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11095-010-0332-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kwok Philip Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Building A15, 2006, Camperdown, NSW, Australia aut NATIONALLICENCE 700 1- Tunsirikongkon Amolnat Department of Pharmaceutics and Industrial Pharmacy Faculty of Pharmaceutical Sciences, Chulalongkorn University, Phyathai Road, Patumwan, 10330, Bangkok, Thailand aut NATIONALLICENCE 700 1- Glover William GSK Consumer Health, 82 Hughes Avenue, 2115, Ermington, NSW, Australia aut NATIONALLICENCE 700 1- Chan Hak-Kim Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Building A15, 2006, Camperdown, NSW, Australia aut NATIONALLICENCE 773 0- Pharmaceutical Research Springer US; http://www.springer-ny.com 28/4(2011-04-01), 788-796 0724-8741 28:4<788 2011 28 11095 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer